(Q37840389)

English

Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer

scientific article published on 18 February 2011

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Debra L. Richardson

object named as

Debra L Richardson

2

0 references

object named as

Floor J Backes

10

0 references

object named as

David E Cohn

9

0 references

author name string

David M O'Malley

1

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Patrick S Rheaume

3

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Ritu Salani

4

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Eric L Eisenhauer

5

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Georgia A McCann

6

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Jeffrey M Fowler

7

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Larry J Copeland

8

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

language of work or name

0 references

publication date

18 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

121

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

269-272

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.009

7 January 2021

Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.009

7 January 2021

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.009

7 January 2021

Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.009

7 January 2021

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.009

7 January 2021

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.009

7 January 2021

Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.009

7 January 2021

A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.009

7 January 2021

Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.009

7 January 2021

Bevacizumab in the treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.009

7 January 2021

Bevacizumab toxicities and their management in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.009

7 January 2021

Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.009

7 January 2021

Sustained progression-free survival with weekly paclitaxel and bevacizumab in recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.009

7 January 2021

CA125 response: can it replace the traditional response criteria in ovarian cancer?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.009

7 January 2021

Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.009

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.01.009

7 January 2021

Identifiers

10.1016/J.YGYNO.2011.01.009

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

release_j6kita47bretlhwv47yrlbk4f4

1 reference

https://api.fatcat.wiki/v0/release/j6kita47bretlhwv47yrlbk4f4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37840389&oldid=2147793083"